• Jonas Willmann, Nicolaus Andratschke, Jens Peter Klußmann, Jürgen E Gschwend, Ghazaleh Tabatabai, and Maximilian Niyazi.
• Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, Cologne, Germany; Rechts der Isar Medical Center, Department of Urology, Technical University Munich, Munich, Germany; Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Tubingen, Germany; Universitätsklinik für Radioonkologie, Universitätsklinikum Tübingen, Germany; Center for Neurooncology, Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
• Dtsch Arztebl Int. 2024 Nov 1; 121 (22): 725732725-732.

BackgroundThe treatment options for patients with progressive malignant tumors despite primary radiotherapy are often limited. In selected cases, re-irradiation can be offered. This article concerns the selection criteria and results of re-irradiation for certain types of cancer.MethodsThis review is based on pertinent publications retrieved by a selective search in PubMed, with particular attention to glio - blastoma, head and neck tumors, and prostatic carcinoma.ResultsThe published studies of re-irradiation are few in number and often of limited methodological quality. For glioblastoma, a randomized controlled trial (RCT) found that adding re-irradiation to treatment with bevacizumab yielded no significant improvement in either median progression-free survival or median overall survival (hazard ratio [HR] 0.73; p = 0.05 and HR 0.98; p = 0.46, respec - tively). Re-irradiation is a treatment option for locoregional recurrences of head and neck tumors after primary radiotherapy, but it carries a risk of serious side effects. For unresectable recurrences of nasopharyngeal carcinoma, an RCT has shown that hyperfractionated re-irradiation is more effective than normofractionated re-irradiation (overall survival: HR 0.54, p = 0.014). For locally recurrent prostatic carcinoma after radiotherapy, re-irradiation can yield good oncologic outcomes with an acceptable level of urogenital and gastrointestinal side effects (5-year recurrence-free survival: stereotactic body radiation therapy (SBRT), 58%; high dose rate (HDR) brachytherapy, 77%; versus salvage prostatectomy, 72%). RCTs on this topic are lacking.ConclusionRe-irradiation is a treatment option for selected cancer patients. As the available scientific evidence is limited, multidisciplinary collaboration and participatory decision-making are particularly important.

26 keywords...

hide…